Central
adrenal insufficiency (AI) due to isolated
adrenocorticotropic hormone (
ACTH) deficiency (IAD) has been recently associated with
immune checkpoint inhibitor (ICI)
therapy. Our aim was to analyze the prevalence, clinical characteristics, and therapeutic outcomes in
cancer patients with IAD induced by ICI
therapy. A retrospective and multicenter study was performed. From a total of 4447
cancer patients treated with ICI
antibodies, 37 (0.8%) (23 men (62.2%), mean age 64.7 ± 8.3 years (range 46-79 years)) were diagnosed with IAD. The
tumor most frequently related to IAD was
lung cancer (n = 20, 54.1%), followed by
melanoma (n = 8, 21.6%). The most common ICI antibody inhibitors reported were
nivolumab (n = 18, 48.6%),
pembrolizumab (n = 16, 43.2%), and
ipilimumab (n = 8, 21.6%). About half of the patients (n = 19, 51.4%) had other immune-related adverse events, mainly endocrine adverse effects (n = 10, 27.0%). IAD was diagnosed at a median time of 7.0 months (IQR, 5-12) after starting
immunotherapy. The main reported symptom at presentation was
fatigue (97.3%), followed by
anorexia (81.8%) and general malaise (81.1%). Mean follow-up time since IAD diagnosis was 15.2 ± 12.5 months (range 0.3-55 months). At last visit, all patients continued with hormonal deficiency of
ACTH. Median overall survival since IAD diagnosis was 6.0 months. In conclusion, IAD is a rare but a well-established complication associated with ICI
therapy in
cancer patients. It develops around 7 months after starting the treatment, mainly anti-PD1
antibodies. Recovery of the corticotropic axis function should not be expected.